Thalys(SH:603716)2024-04-26 15:11Financial Performance - In Q1 2024, the company achieved operating revenue of CNY 485.12 million, an increase of 9.24% compared to the same period last year[5] - The net profit attributable to shareholders was CNY 3.16 million, a significant turnaround from a net loss of CNY 14.91 million in the same period last year[6] - Total operating revenue for Q1 2024 reached ¥485,121,921.87, an increase of 9.3% compared to ¥444,069,353.53 in Q1 2023[22] - Gross profit for Q1 2024 was ¥110,107,507.14, compared to ¥88,758,336.98 in Q1 2023, indicating a significant improvement[23] - Net profit for Q1 2024 was ¥14,336,396.76, a turnaround from a net loss of ¥6,651,427.65 in Q1 2023[24] - The company reported a total comprehensive income of ¥14,385,321.18 for Q1 2024, compared to a loss of ¥7,511,690.31 in Q1 2023[24] - Earnings per share for Q1 2024 were ¥0.02, compared to a loss per share of ¥0.07 in Q1 2023[24] Cash Flow and Investments - The company reported a net cash flow from operating activities of -CNY 27.15 million, a decrease of 170.26% year-on-year[5] - Cash flow from operating activities in Q1 2024 was negative at -¥27,149,003.40, down from a positive cash flow of ¥38,642,551.81 in Q1 2023[27] - The net cash flow from investment activities was -$3,649,062.54, indicating a significant outflow compared to the previous quarter's net cash flow of $23,031,977.63[29] - Total cash inflow from financing activities amounted to $38,800,117.40, while cash outflow was $102,191,744.79, resulting in a net cash flow of -$63,391,627.39 from financing activities[29] - The ending balance of cash and cash equivalents decreased to $169,645,340.85 from an initial balance of $263,834,993.02, reflecting a net decrease of $94,189,652.17[29] - The company received $20,663,895.00 in cash from borrowings during the quarter, contributing to the overall financing activities[29] - Cash received from investments totaled $264,854.00, primarily from minority shareholders[29] - The company reported cash outflows of $55,700,000.00 for debt repayment during the quarter[29] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3.31 billion, a decrease of 1.07% from the end of the previous year[6] - The company's current assets totaled RMB 2,365,756,856.13, down from RMB 2,394,715,901.95, indicating a decrease of about 1.21%[18] - The company's total liabilities amounted to RMB 1,899,817,904.13, which is a decrease from RMB 1,935,609,849.19, reflecting a reduction of approximately 1.85%[19] - The total liabilities decreased to ¥1,989,210,908.70 in Q1 2024 from ¥2,027,091,715.60 in Q1 2023, showing a reduction of approximately 1.9%[22] - The company’s non-current assets totaled RMB 940,429,191.52, a slight decrease from RMB 947,067,988.12, indicating a decline of about 0.77%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,622[13] - The top shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 10.7% of the shares, totaling 21,642,540 shares[13] - The company reported a total of 12,441,040 shares held in the repurchase special securities account, accounting for 6.18% of the total share capital as of March 31, 2024[15] Research and Development - Research and development expenses increased by 30.73%, reflecting the company's commitment to enhancing its R&D capabilities[11] - Research and development expenses increased to ¥9,739,943.89 in Q1 2024, up from ¥7,450,644.90 in Q1 2023, reflecting a focus on innovation[23] Cost Management - The company reduced total expenses (sales, management, R&D, and financial expenses) by CNY 20.26 million, a decline of 18.65% year-on-year, indicating improved cost control[7] - Total operating costs for Q1 2024 were ¥465,044,414.73, up from ¥455,311,016.55 in Q1 2023, reflecting a rise of 2.6%[22] Other Information - The company received government subsidies amounting to CNY 1.81 million, contributing positively to its financial performance[9] - The company did not apply new accounting standards or interpretations for the first quarter of 2024[29] - The report was published by the board of directors of Celis Medical Technology Group Co., Ltd. on April 27, 2024[30]